South China Morning Post CENTER (0.0) Reliability: 7.5/10

China’s Hansoh and Leads Biolabs clinch US$2.5 billion in global drug licensing deals

✍️ Eric Ng 📅 October 17, 2025 01:06 PM 🕐 Scraped: October 17, 2025

Summary: Two mainland biotech firms win global attention as Roche and Dianthus sign major licensing pacts, highlighting China’s growing role in next-generation drug development.

Two Chinese drug developers have signed licensing deals that could yield as much as US$2.5 billion in performance-based payments, underscoring growing international confidence in China’s life sciences sect

📰

Continue Reading on South China Morning Post

This preview shows approximately 15% of the article. Read the full story on the publisher's website to support quality journalism.

Read Full Article →

How do you feel about this article?

Read Original Article →

📝 Article Information

Author

Eric Ng

Original Publisher

🌍 South China Morning Post

CENTER Bias (0.0)

Published Date

October 17, 2025 at 01:06 PM

ℹ️

Disclaimer

ArkforgeAI.com - Newsource is a news aggregation platform. We do not create, write, or produce original news content. All articles are sourced from their respective publishers and remain the property of their original creators. We analyze and aggregate news from multiple sources to provide diverse perspectives across the political spectrum.

The content displayed here is for informational purposes only. For the complete and original article, please visit the source's website using the "Read Original Article" link above.

Desktop Only